Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
May 14
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedMay 14, 2025
DataAggregated Company Financials
Companies9
- 7D-1.6%
- 3M3.0%
- 1Y51.0%
- YTD19.2%
Over the last 7 days, the Life Sciences industry has dropped 1.6%, driven by pullbacks in Genscript Biotech and XtalPi Holdings of 5.2% and 6.0%, respectively. Meanwhile, Viva Biotech Holdings actually outperformed within the industry, gaining 7.4% in the last week. This takes the industry's 12 month performance to a gain of 51%. As for the next few years, earnings are expected to grow by 31% per annum.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 14 May 2025 | HK$187.5b | HK$35.9b | HK$2.6b | 25.9x | 72.6x | 5.2x |
| Fri, 11 Apr 2025 | HK$163.6b | HK$35.2b | HK$2.5b | 24.4x | 65x | 4.6x |
| Sun, 09 Mar 2025 | HK$200.0b | HK$35.9b | -HK$1,056,224,592.40 | 44.4x | -189.3x | 5.6x |
| Tue, 04 Feb 2025 | HK$156.2b | HK$36.0b | -HK$1,059,833,639.34 | 52.6x | -147.4x | 4.3x |
| Thu, 02 Jan 2025 | HK$158.6b | HK$35.7b | -HK$1,058,290,871.23 | 58x | -149.9x | 4.4x |
| Sat, 30 Nov 2024 | HK$136.7b | HK$35.9b | -HK$1,058,204,562.01 | 51.7x | -129.1x | 3.8x |
| Mon, 28 Oct 2024 | HK$163.9b | HK$35.7b | -HK$659,995,106.50 | 31.6x | -248.4x | 4.6x |
| Wed, 25 Sep 2024 | HK$143.2b | HK$36.1b | -HK$653,046,298.07 | 26.8x | -219.2x | 4x |
| Fri, 23 Aug 2024 | HK$94.3b | HK$35.9b | HK$2.0b | 16.6x | 47.1x | 2.6x |
| Sun, 21 Jul 2024 | HK$93.2b | HK$33.4b | HK$3.1b | 18.4x | 30.3x | 2.8x |
| Tue, 18 Jun 2024 | HK$92.3b | HK$33.5b | HK$3.1b | 23.2x | 30x | 2.8x |
| Thu, 16 May 2024 | HK$111.2b | HK$33.6b | HK$3.1b | 30.7x | 35.9x | 3.3x |
| Sat, 13 Apr 2024 | HK$111.9b | HK$33.6b | HK$3.1b | 32.2x | 36.1x | 3.3x |
| Mon, 11 Mar 2024 | HK$133.1b | HK$32.3b | HK$3.0b | 59.6x | 44.7x | 4.1x |
| Wed, 07 Feb 2024 | HK$132.2b | HK$32.6b | HK$3.0b | 52x | 43.7x | 4.1x |
| Fri, 05 Jan 2024 | HK$203.8b | HK$32.4b | HK$3.0b | 90.7x | 68x | 6.3x |
| Sun, 03 Dec 2023 | HK$276.7b | HK$32.4b | HK$3.0b | 94.2x | 92x | 8.5x |
| Tue, 31 Oct 2023 | HK$269.7b | HK$30.1b | HK$2.7b | 48.4x | 101.3x | 9x |
| Thu, 28 Sep 2023 | HK$241.3b | HK$30.1b | HK$2.7b | 42.6x | 90.5x | 8x |
| Sat, 26 Aug 2023 | HK$235.8b | HK$30.3b | HK$2.7b | 23.5x | 85.9x | 7.8x |
| Mon, 24 Jul 2023 | HK$221.3b | HK$28.5b | HK$2.7b | 23.4x | 81x | 7.8x |
| Wed, 21 Jun 2023 | HK$210.8b | HK$28.5b | HK$2.7b | 22.5x | 76.9x | 7.4x |
| Fri, 19 May 2023 | HK$235.9b | HK$29.0b | HK$2.8b | 22x | 83.3x | 8.1x |
| Sun, 16 Apr 2023 | HK$284.5b | HK$29.7b | HK$3.0b | 18.4x | 94.8x | 9.6x |
| Tue, 14 Mar 2023 | HK$261.1b | HK$26.4b | HK$2.1b | 23x | 126x | 9.9x |
| Thu, 09 Feb 2023 | HK$336.7b | HK$26.7b | HK$2.1b | 26.7x | 157.7x | 12.6x |
| Sat, 07 Jan 2023 | HK$343.6b | HK$26.4b | HK$2.1b | 28.1x | 164.7x | 13x |
| Mon, 05 Dec 2022 | HK$268.9b | HK$25.8b | HK$2.0b | 26.8x | 137.8x | 10.4x |
| Wed, 02 Nov 2022 | HK$210.6b | HK$25.2b | HK$1.8b | 20.1x | 118.1x | 8.3x |
| Fri, 30 Sep 2022 | HK$248.0b | HK$25.5b | HK$1.8b | 20.8x | 134.1x | 9.7x |
| Sun, 28 Aug 2022 | HK$373.3b | HK$25.4b | HK$2.8b | 11x | 134x | 14.7x |
| Tue, 26 Jul 2022 | HK$410.5b | HK$22.3b | HK$2.0b | 12.7x | 200.7x | 18.4x |
| Thu, 23 Jun 2022 | HK$361.0b | HK$22.5b | HK$2.1b | 15x | 172.8x | 16.1x |
| Sat, 21 May 2022 | HK$296.6b | HK$22.4b | HK$2.1b | 13.4x | 143.1x | 13.2x |
Price to Earnings Ratio
143.1x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 72.6x which is higher than its 3-year average PE of 34.1x.
- The 3-year average PS ratio of 7.6x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 7.6% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 2.09% | |
| Healthcare | -3.00% | |
| Life Sciences | -1.62% | |
| Clinical Research and Equipment | -1.62% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$23.80 | 9.7% +HK$8.5b | 64.1% | PE26.6x | |
| 2268 WuXi XDC Cayman | HK$38.50 | 9.7% +HK$4.1b | 126.5% | PE40x | |
| 1873 Viva Biotech Holdings | HK$1.66 | 16.1% +HK$484.4m | 159.4% | PE19.3x | |
| 1521 Frontage Holdings | HK$1.15 | 2.7% +HK$60.7m | -10.2% | PE377x | |
| 8225 China Health Group | HK$0.17 | 10.6% +HK$15.9m | 39.2% | PS5.8x |
